JP2020502133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502133A5 JP2020502133A5 JP2019531808A JP2019531808A JP2020502133A5 JP 2020502133 A5 JP2020502133 A5 JP 2020502133A5 JP 2019531808 A JP2019531808 A JP 2019531808A JP 2019531808 A JP2019531808 A JP 2019531808A JP 2020502133 A5 JP2020502133 A5 JP 2020502133A5
- Authority
- JP
- Japan
- Prior art keywords
- lung
- pharmaceutical composition
- fibrosis
- plasminogen
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 210000004072 lung Anatomy 0.000 claims 10
- 206010016654 Fibrosis Diseases 0.000 claims 7
- 102000013566 Plasminogen Human genes 0.000 claims 7
- 108010051456 Plasminogen Proteins 0.000 claims 7
- 230000006378 damage Effects 0.000 claims 7
- 230000004761 fibrosis Effects 0.000 claims 7
- 102000008186 Collagen Human genes 0.000 claims 5
- 108010035532 Collagen Proteins 0.000 claims 5
- 229920001436 collagen Polymers 0.000 claims 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000009278 visceral effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000034712 Rickettsia Infections Diseases 0.000 claims 1
- 206010061495 Rickettsiosis Diseases 0.000 claims 1
- 241000589970 Spirochaetales Species 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000481 chemical toxicant Toxicity 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 239000003344 environmental pollutant Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- -1 for example Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002443 hepatoprotective effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000006749 inflammatory damage Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000004041 inotropic agent Substances 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110174 | 2016-12-15 | ||
| PCT/CN2017/089057 WO2018107697A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗肺纤维化的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502133A JP2020502133A (ja) | 2020-01-23 |
| JP2020502133A5 true JP2020502133A5 (enExample) | 2020-07-30 |
| JP7213553B2 JP7213553B2 (ja) | 2023-01-27 |
Family
ID=62557850
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11154595B2 (enExample) |
| EP (4) | EP3556380A4 (enExample) |
| JP (4) | JP7213552B2 (enExample) |
| CN (4) | CN110114080A (enExample) |
| CA (4) | CA3046669A1 (enExample) |
| TW (6) | TWI752044B (enExample) |
| WO (5) | WO2018107697A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556380A4 (en) | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
| ES3036897T3 (en) | 2017-06-19 | 2025-09-25 | Talengen Int Ltd | Plasminogen for use in treating parkinson's and alzheimer's disease |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| TWI788779B (zh) * | 2020-02-11 | 2023-01-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療病毒性肺炎的方法和藥物 |
| CN114984032B (zh) * | 2022-06-27 | 2023-07-07 | 四川大学 | Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| EP0910571B1 (en) | 1996-05-03 | 2005-07-20 | Abbott Laboratories | Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| CA2295925A1 (en) | 1997-06-26 | 1999-01-07 | Karolinska Innovations Ab | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| WO2000010506A2 (en) | 1998-08-20 | 2000-03-02 | University Of Vermont And State Agriculture College | Angiogenesis inhibitors and uses thereof |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU2002239414A1 (en) | 2000-11-02 | 2002-05-27 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| MXPA00011713A (es) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050124036A1 (en) | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| US20040043026A1 (en) | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| CA2509170A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| AU2005277137A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as PAI-1 inhibitors |
| CN101573134B (zh) * | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| MX2010005947A (es) | 2007-11-29 | 2010-09-10 | Talecris Biotherapeutics Inc | Plasmina modificada de forma recombinante. |
| WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| NZ597452A (en) * | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| NZ600160A (en) | 2009-11-07 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120114652A1 (en) | 2010-05-03 | 2012-05-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| RU2604807C2 (ru) * | 2011-01-05 | 2016-12-10 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| US9655973B2 (en) | 2012-03-09 | 2017-05-23 | Vascular Biosciences | Orally active, cell-penetrating homing peptide and methods of using same |
| KR101467109B1 (ko) | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물 |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| EA033403B1 (ru) | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| WO2015026494A2 (en) | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
| TR201907379T4 (tr) * | 2014-02-21 | 2019-06-21 | Astellas Pharma Inc | Yeni anti-insan PAI-1 antikoru. |
| HUE068351T2 (hu) | 2014-12-19 | 2024-12-28 | Kedrion Biopharma Inc | Plazminogént tartalmazó gyógyszerkészítmény és annak felhasználásai |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| EP3391902B1 (en) | 2015-12-18 | 2023-10-18 | Talengen International Limited | Plasminogen for use in the treatment of diabetic angiocardiopathy |
| CN106890318A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病性心脏病的新方法 |
| CN106890320A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| CN108463236A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
| CN106890324A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN115845037A (zh) | 2015-12-18 | 2023-03-28 | 泰伦基国际有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| EP3556380A4 (en) | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| CA3047170A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| TWI763680B (zh) | 2016-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備藥物中的用途 |
| TW201822809A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療高脂血症的方法 |
| ES3036897T3 (en) | 2017-06-19 | 2025-09-25 | Talengen Int Ltd | Plasminogen for use in treating parkinson's and alzheimer's disease |
-
2017
- 2017-06-19 EP EP17880059.5A patent/EP3556380A4/en active Pending
- 2017-06-19 CA CA3046669A patent/CA3046669A1/en not_active Abandoned
- 2017-06-19 EP EP17881523.9A patent/EP3556389A4/en active Pending
- 2017-06-19 EP EP17880398.7A patent/EP3556382A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089057 patent/WO2018107697A1/zh not_active Ceased
- 2017-06-19 TW TW106120454A patent/TWI752044B/zh active
- 2017-06-19 CN CN201780078123.9A patent/CN110114080A/zh active Pending
- 2017-06-19 EP EP17882248.2A patent/EP3556395A4/en active Pending
- 2017-06-19 TW TW106120457A patent/TW201822790A/zh unknown
- 2017-06-19 US US16/470,179 patent/US11154595B2/en active Active
- 2017-06-19 TW TW110101502A patent/TW202123955A/zh unknown
- 2017-06-19 CN CN201780078169.0A patent/CN110191718A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089058 patent/WO2018107698A1/zh not_active Ceased
- 2017-06-19 TW TW106120453A patent/TWI734798B/zh active
- 2017-06-19 US US16/470,186 patent/US11071772B2/en active Active
- 2017-06-19 CA CA3046666A patent/CA3046666A1/en active Pending
- 2017-06-19 JP JP2019531805A patent/JP7213552B2/ja active Active
- 2017-06-19 CN CN201780078132.8A patent/CN110121358A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089056 patent/WO2018107696A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089054 patent/WO2018107694A1/zh not_active Ceased
- 2017-06-19 JP JP2019531808A patent/JP7213553B2/ja active Active
- 2017-06-19 JP JP2019531811A patent/JP7313058B2/ja active Active
- 2017-06-19 US US16/470,172 patent/US11219669B2/en active Active
- 2017-06-19 TW TW106120449A patent/TWI657823B/zh active
- 2017-06-19 US US16/470,162 patent/US20190314466A1/en not_active Abandoned
- 2017-06-19 TW TW106120456A patent/TWI670075B/zh active
- 2017-06-19 WO PCT/CN2017/089053 patent/WO2018107693A1/zh not_active Ceased
- 2017-06-19 CA CA3047174A patent/CA3047174A1/en not_active Abandoned
- 2017-06-19 CA CA3046671A patent/CA3046671C/en active Active
- 2017-06-19 JP JP2019531806A patent/JP2020502132A/ja active Pending
- 2017-06-19 CN CN201780078166.7A patent/CN110139668A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502133A5 (enExample) | ||
| Ou et al. | The cGAS-STING pathway: a promising immunotherapy target | |
| D’Anna et al. | Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease | |
| Huckle et al. | Prophylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibiotics | |
| Knippenberg et al. | Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin | |
| Kwapisz et al. | Platelet-rich plasma for elbow pathologies: a descriptive review of current literature | |
| JP5713672B2 (ja) | 結核のワクチンおよびその使用方法 | |
| Bassetti et al. | Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA) | |
| Chan et al. | Inhaled delivery of anti-pseudomonal phages to tackle respiratory infections caused by superbugs | |
| CN110121358A (zh) | 一种预防和治疗肺纤维化的方法 | |
| JP2020511413A5 (enExample) | ||
| Zalagh et al. | Chronic rhinorrhea revealing an actinomycotic rhinolithiasis with ectopic tooth | |
| Castagnola et al. | Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant | |
| Palaniappan et al. | Therapeutic efficacy of bacteriophages | |
| Kumari et al. | Antimicrobial peptides in Tuberculosis: Insights into the immunomodulatory mechanisms | |
| JP2005525361A (ja) | 急性発作後の予防的治療用の作用物質 | |
| JP2012517472A (ja) | 縮小ゲノム細菌を含む敗血症治療用組成物 | |
| Vázquez et al. | Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: a perspective from Spain. Microorganisms 2022; 10: 717 | |
| Mukherjee et al. | The Use of Bacteriophages to Help Treat Multidrug-Resistant (MDR) Tuberculosis | |
| Sethi et al. | Safety and tolerability of ARD-3150, inhaled liposomal ciprofloxacin, in patients with bronchiectasis and chronic pseudomonas aeruginosa infection: results from two phase 3 trials | |
| HASHEMI et al. | Effects of dexamethasone on clinical outcome in patients with severe Crimean-Congo hemorrhagic fever | |
| Kerget et al. | Evaluation of the Roflumilast Effect Supplemented with Linezolid in Pleural Empyema in Rats Caused by Intrapleural Staphylococcus aureus Inoculation | |
| Annobil et al. | Bronchiectasis due to lipid aspiration in childhood: clinical and pathological correlates | |
| Byun et al. | Respiratory delivery of bacteriophages for the treatment of lung infections | |
| Lin et al. | Pulmonary azygous lobe |